Tag: Astrazeneca
AstraZeneca: Two new innovative statutes for Enhertu
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
AstraZeneca: Legal action against the IRA law in the USA
(CercleFinance.com) – AstraZeneca announced on Friday that it has launched legal action in the United States to protect access to drugs against cancer and rare diseases, which it considers threatened…
AstraZeneca: legal action against the IRA law in the USA
(CercleFinance.com) – AstraZeneca announced on Friday that it has launched legal action in the United States to protect access to drugs against cancer and rare diseases, which it considers threatened…
AstraZeneca: CDC recommendation for Beyfortus
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
AstraZeneca: New approval for Enhertu in China
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
AstraZeneca: rebound of the title, the correction considered excessive
(CercleFinance.com) – AstraZeneca shares rebounded by almost 2% on the London Stock Exchange on Tuesday, some analysts deeming the heavy fall in value yesterday to be excessive. The title of…
AstraZeneca: AlphaValue detects ‘a good entry point’
(CercleFinance.com) – AlphaValue confirms its buy rating on AstraZeneca stock with an unchanged price target of 14,158 pence, the day after a session that saw the stock drop nearly 8%…
AstraZeneca: Rebound of the title, the correction considered excessive
(CercleFinance.com) – AstraZeneca shares rebounded by almost 2% on the London Stock Exchange on Tuesday, some analysts deeming the heavy fall in value yesterday to be excessive. The title of…
Market: AstraZeneca retreats after a therapeutic trial on lung cancer deemed disappointing
PARIS (Reuters) – AstraZeneca said on Monday that a late-stage lung cancer treatment has slowed the progression of the disease, but analysts fear the drug’s benefits may not be so…
AstraZeneca: a clinical study struggles to convince
(CercleFinance.com) – The title AstraZeneca shows a heavy decline on Monday on the London Stock Exchange following the presentation by the pharmaceutical group of results considered mixed in lung cancer.…
Damage caused by corona vaccination?: Court in Rottweil gives little hope to Biontech plaintiffs
Damage caused by corona vaccination? Court in Rottweil gives little hope to Biontech plaintiffs 7/3/2023 6:56 p.m In Rottweil and Bamberg, two processes are starting about possible damage caused by…
AstraZeneca: A clinical study struggles to convince
(CercleFinance.com) – The title AstraZeneca shows a heavy decline on Monday on the London Stock Exchange following the presentation by the pharmaceutical group of results considered mixed in lung cancer.…